Allergan USA Inc.
This article is outside of Ballotpedia's coverage scope and does not receive scheduled updates. If you would like to help our coverage scope grow, consider donating to Ballotpedia.
| Allergan USA, Inc. | |
 | |
| Basic facts | |
| Location: | Parsippany, N.J. |
| Top official: | Brenton L. Saunders, President and CEO |
| Year founded: | 2004 |
| Website: | Official website |
As of 2016, Allergan USA Inc. was the U.S. subsidiary of Allergan plc, a global pharmaceutical company headquartered in Dublin, Ireland. In addition to Botox and Restasis, Allergan's top-selling brands, the company researched, developed, and manufactured a diverse portfolio of pharmaceuticals and medical products.[1][2][3]
Background
Allergan USA Inc. was established in 2004 as Esprit Pharma, Inc. The company specialized in the development of genitourinary drugs, including the overactive bladder treatment Sanctura. In 2007, Allergan plc, a global pharmaceutical company, acquired Esprit Pharma Inc. with the intention of expanding its interest in the genitourinary market. Following the acquisition, Esprit Pharma Inc. was renamed Allergan USA Inc. The company's U.S. headquarters were located in Parsippany, New Jersey, as of 2016.[2][5][6]
Allergan's research and development process, Open Science, focused on producing products that address the "central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories." As of October 7, 2016, Allergan maintained commercial, manufacturing, or research facilities in more than 100 countries.[2]
Political activity
Allergan USA Inc. aimed to support its public policy priorities through participation in the U.S. political process. The company made political contributions to federal candidates through its federal political action committee, Allergan, Inc. PAC. In addition, the group made direct political contributions within legal guidelines to state and local candidates and political committees. As of 2016, Allergan was also a member of several professional industry and trade organizations, such as Pharmaceutical Research and Manufacturers of America (PhRMA).[7]
Lobbying
The following table displays Allergan USA Inc.'s federal lobbying expenditures according to the Center for Responsive Politics:[8]
| Federal lobbying expenditures for Allergan USA Inc., 2010-2014 | ||
|---|---|---|
| Year | Total expenditures | |
| 2014 | $2,380,000 | |
| 2013 | $1,650,000 | |
| 2012 | $2,150,000 | |
| 2011 | $2,140,000 | |
| 2010 | $1,500,000 | |
Ballot measure activity
Allergan USA Inc. opposed the 2016 California Drug Price Standards Initiative (Proposition 61), which proposed to regulate drug prices by requiring state agencies to pay the same prices for prescription drugs as the U.S. Department of Veterans Affairs (VA).[4]
Overview of ballot measure support and opposition
The following table details Allergan's ballot measure stances available on Ballotpedia:
| Ballot measure support and opposition for Allergan USA Inc. | |||
|---|---|---|---|
| Ballot measure | Year | Position | Status |
| California Proposition 61, Drug Price Standards (2016) | 2016 | Opposed[4] |  Defeated
|
Leadership
Allergan plc, the parent company of Allergan USA Inc., had the following leadership as of 2016:[9]
- Paul M. Bisaro, Executive chairman of Allergan and the board of directors
- Brenton L. Saunders, Chief executive officer and president
- Robert Stewart, Chief operating officer
- William Meury, Chief commercial officer
- C. David Nicholson, Chief R&D officer
- Maria Teresa Hilado, Chief financial officer
- Robert D. Bailey, Chief legal officer and corporate secretary
- Karen Ling, Chief human resources officer
- Alex Kelly, Chief communications officer
Recent news
The link below is to the most recent stories in a Google news search for the terms Allergan USA Inc.. These results are automatically generated from Google. Ballotpedia does not curate or endorse these articles.
See also
- California Proposition 61, Drug Price Standards (2016)
- California 2016 ballot measures
- Healthcare policy in California
- Pharmaceutical Research and Manufacturers of America (PhRMA)
External links
Footnotes
- ↑ U.S. Securities and Exchange Commission, "Entities of Allergan, Inc.," accessed October 7, 2016
- ↑ 2.0 2.1 2.2 Allergan, "Company profile," accessed October 7, 2016
- ↑ The Wall Street Journal, "Allergan Loss Narrows as Botox Revenue Rises," February 22, 2016
- ↑ 4.0 4.1 4.2 California Fair Political Practices Commission, "November 2016 General Election," accessed October 2, 2016, 2016
- ↑ Bloomberg, "Company Overview of Allergan USA, Inc.," accessed October 7, 2016
- ↑ Business Wire, "Allergan, Inc. Announces Agreement to Acquire Esprit Pharma, Inc.," September 19, 2007
- ↑ Allergan, "Political contributions," accessed October 24, 2016
- ↑ Center for Responsive Politics, "Allergan Inc.," accessed October 24, 2016
- ↑ Allergan, "Executive leadership," accessed October 7, 2016
| |||||||
